We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
iShares U.S. Healthcare ETF (IYH) Hits New 52-Week High
For investors seeking momentum, iShares U.S. Healthcare ETF (IYH - Free Report) is probably on radar now. The fund just hit a 52-week high and is up nearly 27.7% from its 52-week low price of $137.30/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:
IYH in Focus
This fund looks to track the performance of the healthcare sector of the U.S. equity market. The fund is tilted toward the Pharmaceuticals sector with about 33.7% exposure, followed by Biotechnology (24.5%). Johnson & Johnson, Pfizer Inc and Unitedhealth Group Inc are the top three stocks of the fund. The net expense ratio of the fund is 0.44% (see Health Care ETFs here).
Why the Move?
The fund benefited from the upbeat earnings from Johnson & Johnson and Unitedhealth Group released lately. UnitedHealth Group comfortably beat the Zacks Consensus Estimate on membership growth. Johnson & Johnson also beat the Zacks Consensus Estimate for both earnings and sales. Both stocks gained considerably after earnings.
More Gains Ahead?
The fund has a Zacks Rank #2 (Buy). It seems that this fund might stay strong given a positive weighted alpha of 21.40. As a result, there is still some promise for investors who want to ride on this surging ETF.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>